BioTech Breakthrough’s Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry “We believe EsoGuard, the first and only commercially available diagnostic ...
EsoGuard 2.0 incorporates advanced molecular techniques and leverages improvements in sample DNA yields and processes to enhance assay performance and lower costs The results of the analytical ...
Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard esophageal precancer testing ...
LONG BEACH, Calif. (KABC) -- Many people experience occasional acid reflux. But if you have it all the time, it could lead to a very serious condition and in some cases, cancer. Now, there's a new ...
NEW YORK--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned ...
Lucid Diagnostics' (NASDAQ:LUCD) EsoGuard test could get Medicare coverage soon, according to recent commentary from BTIG analysts. Analysts at BTIG said that during a day of investor meetings with ...
NEW YORK--(BUSINESS WIRE)--Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results